These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26395316)

  • 21. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost Effectiveness Analysis of Knee Osteoarthritis Treatment.
    Stan G; Orban H; Orban C
    Chirurgia (Bucur); 2015; 110(4):368-74. PubMed ID: 26305202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
    Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses.
    Angevine PD; Berven S
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S9-15. PubMed ID: 25299265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease.
    Okubo R; Kondo M; Hoshi SL; Yamagata K
    Sleep Breath; 2015 Sep; 19(3):1081-92. PubMed ID: 25643768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).
    Mehrez A; Gafni A
    Pharmacoeconomics; 1992 May; 1(5):338-45. PubMed ID: 10146998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome assessment in cardiovascular cost-benefit studies.
    O'Brien B; Rushby J
    Am Heart J; 1990 Mar; 119(3 Pt 2):740-7; discussion 747-8. PubMed ID: 2106767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QALYs and mental health care.
    Chisholm D; Healey A; Knapp M
    Soc Psychiatry Psychiatr Epidemiol; 1997 Feb; 32(2):68-75. PubMed ID: 9050347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation in the field of cardiology: theory and practice.
    van Hout BA; Goes ES; Grijseels EW; van Ufford MA
    Prog Cardiovasc Dis; 1999; 42(2):167-73. PubMed ID: 10555117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating QALYs with a heavy dose of social values: is the cure worth the cost?
    Matchar DB
    Med Care; 2000 Sep; 38(9):889-91. PubMed ID: 10982110
    [No Abstract]   [Full Text] [Related]  

  • 34. DALYs and QALYs in developing countries.
    Zarate V
    Health Aff (Millwood); 2007; 26(4):1197-8. PubMed ID: 17630466
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of cardiovascular disease spending.
    Miller G; Cohen JT; Roehrig C
    J Am Coll Cardiol; 2012 Nov; 60(20):2123-4. PubMed ID: 23137531
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost and benefit in cardiovascular imaging: the quest for economic sustainability.
    Leo CG; Carpeggiani C; Picano E
    Int J Cardiovasc Imaging; 2010 Aug; 26(6):613-6. PubMed ID: 20437104
    [No Abstract]   [Full Text] [Related]  

  • 37. A brief introduction to health economics.
    Waugh N; Mistry H
    Knee Surg Sports Traumatol Arthrosc; 2019 Jun; 27(6):1704-1707. PubMed ID: 30729981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should we maximise QALYs? : a debate with respect to peak-end evaluation.
    Oliver A
    Appl Health Econ Health Policy; 2004; 3(2):61-6. PubMed ID: 15702942
    [No Abstract]   [Full Text] [Related]  

  • 39. QALYs: The Math Doesn't Work.
    Sawhney TG; Dobes A; O'Charoen S
    J Health Econ Outcomes Res; 2023; 10(2):10-13. PubMed ID: 37522031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory bodies and health care systems should systematically evaluate the safety and cost-effectiveness of new cardiovascular treatments in health care registries using prospectively designed protocols.
    Redfors B
    Scand Cardiovasc J; 2024 Dec; 58(1):2343383. PubMed ID: 38695202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.